The Impact of Preoperative Midazolam on Outcome of Elderly Patients (I-PROMOTE) randomized clinical trial 1 enrolled 616 participants aged 65 to 80 years from 9 German hospitals to determine the effects of 3.75-mg oral midazolam given 30 to 45 minutes before general anesthesia induction for elective surgery on patients' satisfaction on postoperative day 1. Patients' satisfaction has become an important component of the quality of perioperative care. 2 Thus, the authors are commended on their work to find answers for a clinical practice.The use of midazolam, a short-acting benzodiazepine, before surgery is common for its anxiolytic and other potential beneficial effects. However, there is a serious concern regarding the contribution of benzodiazepine premedication to perioperative neurocognitive disorders, such as postoperative delirium, especially in elderly patients. 3,4 Importantly, elderly patients are the main population undergoing surgery. 5 The I-PROMOTE trial is important for focusing on this vulnerable population who can have multimorbidity and functional dependency. The trial included cognitive and delirium evaluations as secondary outcomes. However, only the Short Blessed Test, a screen test for cognition, and delirium on postoperative day 1 were examined. These evaluations are not enough for assessing postoperative neurocognitive disorders. Moreover, although the I-PROMOTE trial did not find a difference in postoperative neurocognitive functions, this finding should be interpreted with caution as these were secondary outcomes for which the study was not powered, as stated by the authors.